Restructuring

Daiichi Sankyo shutters another R&D center in an ongoing global overhaul

Daiichi Pharma is closing another R&D division. A month after the Japanese pharma put out the word that it was closing a research facility in India and axing 170 staffers, Daiichi says it will now shutter a research hub in Japan with 150 investigators and transfer the work to other units.

Asubio Pharma has been the discovery engine at Daiichi, based in Kobe and focused on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine.

“We expect the integration of the venture spirit of Asubio Pharma into other Daiichi Sankyo research activities to contribute greatly to improving R&D productivity,” the company said in a statement. Staffers at the facility will get a chance to transfer with the work.

Daiichi joined Takeda in launching a global R&D overhaul in January, looking to selectively slash R&D costs and reallocate the money for pipeline work. Outside of Japan, Daiichi also has operations in Korea, China and Taiwan with a group operating in Munich.

Just about every major, long established pharma company in Europe and the US has undergone an R&D reorganization in the last 5 years, sometimes more than once. Daiichi and Takeda are both following the same path in an era that’s been seeing a major migration into global hubs like Boston/Cambridge and the Bay Area.

Daiichi, though, seems more interested right now in closing research centers rather than opening any new ones in trendier locations.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing